Konrad Kowalski

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Chemistry of organometallic nucleic acid components: personal perspectives and prospects for the future Organometallic modifications of biologically important compounds such as drugs, secondary natural products, peptides, and nucleic acids, to name just a few, represent a well-established strategy for the development of new anticancer and antimicrobial agents.

2. Materials and Methods 2.1. Design of the Study This study was a randomized, double-blind, placebo-controlled clinical trial (NCT04768023) with 12 weeks of vitamin D3 administration in patients with PD who underwent DBS. The research has been approved by the Independent Bioethics Committee for Scientific Research at the Medical University of Gdansk, the number of approval: NKBBN/522-648/2019, date of approval: 3 December 2019.